The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration

In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017. Educational aims To understand the role of Clinical Research Collaborations as the major way in which the European Respiratory Society can stimulate clinical research in different disease areas To understand some of the key features of successful disease registries To review key epidemiological, clinical and translational studies of bronchiectasis contributed by the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) project in the past 5 years To understand the key research priorities identified by EMBARC for the next 5 years Learn about @EMBARCnetwork, a successful @ERStalk Clinical Research Collaboration with @EuropeanLung http://ow.ly/IOl230drGf1

[1]  J. Chalmers,et al.  “The missing ingredient”: the patient perspective of health related quality of life in bronchiectasis: a qualitative study , 2018, BMC Pulmonary Medicine.

[2]  S. Marshall,et al.  Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease , 2018, The Journal of allergy and clinical immunology.

[3]  S. Salvi,et al.  Phenotype characterization of non-cystic fibrosis bronchiectasis in India , 2017 .

[4]  R. Cordovilla,et al.  Etiología de las bronquiectasias en una cohorte de 2.047 pacientes. Análisis del registro histórico español , 2017 .

[5]  C. Olveira,et al.  Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. , 2017, Archivos de bronconeumologia.

[6]  T. Welte,et al.  Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.

[7]  L. Dupont,et al.  Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study , 2017, Chest.

[8]  S. Marshall,et al.  Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis , 2017, American journal of respiratory and critical care medicine.

[9]  A. O'donnell,et al.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry , 2017, Chest.

[10]  S. Sethi,et al.  Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults , 2017, npj Primary Care Respiratory Medicine.

[11]  G. Canonica,et al.  The era of research collaborations: new models for working together , 2017, European Respiratory Journal.

[12]  L. Lynd,et al.  Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review , 2017, Respirology.

[13]  H. Omran,et al.  The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results , 2017, European Respiratory Journal.

[14]  J. Laffey,et al.  Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. , 2016, The Lancet. Respiratory medicine.

[15]  M. Miravitlles,et al.  Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. , 2016, Respiratory medicine.

[16]  J. Khoo,et al.  Bronchiectasis in the Last Five Years: New Developments , 2016, Journal of clinical medicine.

[17]  F. Blasi,et al.  Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis , 2016, International journal of molecular sciences.

[18]  D. Obradović,et al.  Characterization of bronchiectasis in the elderly. , 2016, Respiratory medicine.

[19]  Siân Williams,et al.  European Lung Foundation: from local to global , 2016, Breathe.

[20]  J. Chalmers,et al.  Global impact of bronchiectasis and cystic fibrosis , 2016, Breathe.

[21]  J. Laffey,et al.  Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts , 2016, Thorax.

[22]  O. Sibila,et al.  Diagnostic challenges of bronchiectasis. , 2016, Respiratory medicine.

[23]  J. Chalmers,et al.  Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration , 2016, European Respiratory Journal.

[24]  M. Mantero,et al.  Quality standards for the management of bronchiectasis in Italy: a national audit , 2016, European Respiratory Journal.

[25]  L. Dupont,et al.  The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. , 2016, Respiratory medicine.

[26]  G. Sotgiu,et al.  Clinical phenotypes in adult patients with bronchiectasis , 2016, European Respiratory Journal.

[27]  H. Goossens,et al.  The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. , 2016, The Journal of antimicrobial chemotherapy.

[28]  T. Welte,et al.  The EMBARC European Bronchiectasis Registry: protocol for an international observational study , 2016, ERJ Open Research.

[29]  P. Goeminne,et al.  Bronchiectasis: how to be an orphan with many parents? , 2016, European Respiratory Journal.

[30]  S. Lonni,et al.  Bronchiectasis Rheumatoid Overlap Syndrome(BROS) is an Independent Risk Factor for Mortalityin Patients with Bronchiectasis: A Multicentre CohortStudy , 2016 .

[31]  A. Torres,et al.  Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. , 2015, Annals of the American Thoracic Society.

[32]  L. Smeeth,et al.  Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study , 2015, European Respiratory Journal.

[33]  J. Chalmers,et al.  A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. , 2015, Annals of the American Thoracic Society.

[34]  O. Sibila,et al.  Secreted mucins and airway bacterial colonization in non‐CF bronchiectasis , 2015, Respirology.

[35]  I. Pavord,et al.  A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis , 2015, European Respiratory Journal.

[36]  Andrew J. Oler,et al.  Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. , 2015, American journal of respiratory and critical care medicine.

[37]  T. Welte,et al.  Bronchiectasis in Germany: a population-based estimation of disease prevalence , 2015, European Respiratory Journal.

[38]  P. Powell,et al.  From tokenism to meaningful engagement: best practices in patient involvement in an EU project , 2015, Research Involvement and Engagement.

[39]  J. Chalmers,et al.  Challenges in the development of new therapies for bronchiectasis , 2015, Expert opinion on pharmacotherapy.

[40]  J. Elborn,et al.  Reclaiming the name ‘bronchiectasis’ , 2015, Thorax.

[41]  Stefano Aliberti,et al.  Management of bronchiectasis in adults , 2015, European Respiratory Journal.

[42]  J. Elborn,et al.  COPD–bronchiectasis overlap syndrome , 2015, European Respiratory Journal.

[43]  G. Rogers,et al.  The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. , 2014, The Lancet. Respiratory medicine.

[44]  F. Blasi,et al.  COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity? , 2014, COPD.

[45]  G. Redding,et al.  Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. , 2014, Chest.

[46]  P. Thompson,et al.  Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. , 2014, The Lancet. Respiratory medicine.

[47]  D. Davidson,et al.  Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[48]  D. Bilton,et al.  Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. , 2014, American journal of respiratory and critical care medicine.

[49]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[50]  S. Seys,et al.  The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis , 2014, Respirology.

[51]  A. Hill,et al.  Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. , 2013, Molecular immunology.

[52]  Richard C Boucher,et al.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. , 2013, American journal of respiratory and critical care medicine.

[53]  A. Hill,et al.  Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. , 2013, The Lancet. Respiratory medicine.

[54]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[55]  N. Karalus,et al.  Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[56]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[57]  M. Macek,et al.  Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis , 2010, The Lancet.

[58]  R. Coll,et al.  Diagnóstico y tratamiento de las bronquiectasias , 2008 .

[59]  M. Rosen Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.

[60]  A. O'donnell,et al.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.